Clinical Research Directory

Inclusion Criteria: * Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and cardiac monitoring. * Have a body mass index within the range of 18.5 to 32.0 kilograms per square meter (kg/m²) (inclusive). * Individuals not of childbearing potential (INOCBP) may participate in this trial. Exclusion Criteria: * Have donated 500 milliliters (mL) of blood within 30 days prior to dosing. * Have participated within the last 30 days in a clinical study involving an investigational medicinal product. If the previous investigational product (IP) has a long half-life, 5 half-lives or 30 days (whichever is longer) should have passed. * Participants with hemoglobin outside of the local laboratory normal reference range for age and sex, which is judged to be clinically significant by the investigator. * Participants with an estimated glomerular filtration rate \<90 mL/min/1.73 m². * Have a 12-lead Electrocardiogram (ECG) abnormality that, in the opinion of the investigator, * increases the risks associated with participating in the study * may confound ECG data analysis * Have used or intend to use over-the-counter or prescription medication including dietary or herbal medications within 7 days, or 14 days if the medication is a potential enzyme inducer, or 5 half-lives (whichever is longer), prior to dosing. * Smoke more than 10 cigarettes per day or the equivalent, including electronic cigarettes, and are unable to abide by investigative site smoking restrictions. * Have an average weekly alcohol intake that exceeds 14 units per week (males 65 years of age or younger) and 7 units per week (females and males greater than 65 years of age, if applicable) * Show evidence of * Human immunodeficiency virus (HIV) infection and/or positive human HIV antigen and/or antibodies * hepatitis C and/or positive hepatitis C antibody * hepatitis B and/or positive hepatitis B surface antigen. * Have liver disease. * Any clinical condition or procedure (for example, gastrointestinal obstruction, gastric bypass, or cholecystectomy) that may affect the absorption, distribution, or excretion of the study drug and confound pharmacokinetics (PK) assessment. * Part C Only: * Have history of neuropathy of any cause. * Have impaired hearing or a history of hearing problems. * Have any medical conditions, medical history, or are taking any medications that are contraindicated in the itraconazole prescribing information, such as prior history of hypersensitivity to itraconazole or other azoles. * Participants with any known history of thyroid disease